Botulinum neurotoxin type C protease induces apoptosis in differentiated human neuroblastoma cells by Rust, A. et al.
Oncotarget33220www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 22
Botulinum neurotoxin type C protease induces apoptosis in 
differentiated human neuroblastoma cells
Aleksander Rust1, Charlotte Leese1, Thomas Binz2, Bazbek Davletov1
1University of Sheffield, Firth Court, Sheffield S10 2TN, UK
2Medizinische Hochschule Hannover, Institut für Physiologische Chemie OE4310, 30625 Hannover, Germany
Correspondence to: Bazbek Davletov, e-mail: b.davletov@sheffield.ac.uk
Keywords: neuroblastoma, differentiation, botulinum, toxin, apoptosis
Received: February 24, 2016    Accepted: April 04, 2016    Published: April 21, 2016
ABSTRACT
Neuroblastomas constitute a major cause of cancer-related deaths in young 
children. In recent years, a number of translation-inhibiting enzymes have been 
evaluated for killing neuroblastoma cells. Here we investigated the potential 
vulnerability of human neuroblastoma cells to protease activity derived from 
botulinum neurotoxin type C. We show that following retinoic acid treatment, human 
neuroblastoma cells, SiMa and SH-SY5Y, acquire a neuronal phenotype evidenced 
by axonal growth and expression of neuronal markers. Botulinum neurotoxin type 
C which cleaves neuron-specific SNAP25 and syntaxin1 caused apoptotic death only 
in differentiated neuroblastoma cells. Direct comparison of translation-inhibiting 
enzymes and the type C botulinum protease revealed one order higher cytotoxic 
potency of the latter suggesting a novel neuroblastoma-targeting pathway. Our 
mechanistic insights revealed that loss of ubiquitous SNAP23 due to differentiation 
coupled to SNAP25 cleavage due to botulinum activity may underlie the apoptotic 
death of human neuroblastoma cells.
INTRODUCTION
Neuroblastomas are embryonal tumours arising 
from developing cells of the sympathetic nervous system 
and are the most common form of extra-cranial solid 
tumour in childhood [1]. Current treatment of high risk 
neuroblastoma consists of aggressive chemotherapy 
followed by resection of the primary tumour and focal 
radiotherapy. Treatment is completed with a course 
of retinoic acid to clear up residual tumour cells [2]. 
Despite this intensive, multimodal therapy only around 
40 per cent of children achieve a long term cure and 
neuroblastoma remains the second biggest cause of 
cancer-related deaths in infants [3]. With the introduction 
of humanised antibodies, immunological approaches 
targeting neuroblastoma with high specificity are gaining 
increasing attention [4]. The advantage of precise targeting 
of neuroblastoma cells can be utilised further by attaching 
a cytotoxic cargo to antibodies, for example cytotoxic 
enzymes [5]. Such therapeutic approach holds promise as 
it enables high levels of potency not possible with small 
molecule drugs. The common ribosome-inactivating 
proteins gelonin, saporin and ricin have been investigated 
when coupled to antibodies against neuroblastoma-
enriched receptors, e.g. gangliosides GD2 and GD3 [6-8]. 
However, a major drawback to this ribosome-inhibiting 
approach has been off-target toxicity due to non-specific 
uptake into healthy cells of cytotoxic enzymes [9]. It 
would be important to uncover other cellular pathways 
which can be utilised in the treatment of neuroblastomas. 
Here we investigated the potential vulnerability of human 
neuroblastoma cells to protease activity derived from 
botulinum neurotoxin type C.
Botulinum neurotoxins (BoNTs) are produced 
by bacteria of the Clostridium genus and are the most 
potent neurotoxins known to man [10]. They consist of an 
enzyme (light chain) and a receptor-binding unit (heavy 
chain) connected via a disulphide bond. The heavy chain 
in addition to the neuronal binding domain contains a 
translocation domain necessary for delivery of the enzyme 
into the cytosol [11]. The botulinum enzyme is a protease 
that cleaves so-called SNARE neuronal proteins with 
exquisite specificity [12, 13]. SNARE is an acronym of 
soluble N-ethylmaleimide sensitive factor attachment 
protein receptors. The three SNARE proteins form a strong 
complex needed for the membrane fusion of vesicles 
however their cleavage may also lead to neurotoxicity [14, 
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15]. Specifically, BoNT type C mediates neurotoxicity 
by cleavage and depletion of two SNARE proteins - 
SNAP25 and syntaxin – both being vital for cell membrane 
recycling processes [15, 16]. We have recently shown that 
co-introduction of BoNT type C and type D proteases 
into naïve neuroblastoma cells can cause cytotoxicity 
and induction of apoptosis [17]. However, the need to 
deliver two enzymes into the same cell is not an ideal 
strategy especially if it involves linking to a therapeutic 
antibody. Here we show that botulinum protease type C 
alone is sufficient to cause apoptotic cell death of human 
neuroblastoma cells, but only following differentiation. 
Importantly, direct transduction of translation-inhibiting 
enzymes and the botulinum C protease into retinoic acid-
treated neuroblastoma cells revealed stronger potency of the 
latter suggesting a novel neuroblastoma-targeting pathway.
RESULTS
Undifferentiated neuroblastoma cells are 
resistant to BoNT/C
The effect of full BoNT/C neurotoxin was first 
tested on undifferentiated human SH-SY5Y and SiMa 
neuroblastoma cells [18, 19]. SNARE cleavage in both 
cell lines was analysed after incubation with BoNT/C at 
100 nM for 72 hours. Immunoblotting revealed a massive 
cleavage of Syntaxin 1 and SNAP25 in neuroblastoma 
cells (Figure 1A). Despite the observed SNARE cleavage, 
cells continued to grow normally, as measured by a cell-
counting tetrazolium salt-based assay, with no gross cellular 
abnormalities detected by microscopy (Figure 1B). Thus, 
when undifferentiated, neuroblastoma cells do not likely 
require SNAP25 or syntaxin 1 for cell survival and growth.
Retinoic acid and removal of serum cause robust 
neuronal differentiation of SiMa cells
Differentiation of SiMa neuroblastoma cells 
has been shown to greatly enhance their sensitivity 
to BoNT type A paving the way for a subnanomolar 
sensitive assay for potency of relevant therapeutic 
products [18]. We therefore investigated whether 
differentiation of SiMa cells would also impact on 
BoNT/C effects. SiMa cells were grown on collagen, 
laminin or poly-L-lysine for 72 hours either in a serum-
supplemented medium or in serum-free medium with 
B27 supplement. Among the substrates tested, laminin 
was best to promote a neuronal phenotype and was 
used for optimisation of differentiation (Supplementary 
Figure S1A). Addition of retinoic acid, often used to 
induce neuronal differentiation [20], led to a marked 
increase in neurite outgrowth and concomitantly 
reduced cell growth over 10 days confirming terminal 
cell differentiation (Supplementary Figure S1B, S1C). 
SiMa cells grown on laminin in serum-free medium in 
the presence of retinoic acid will henceforth be referred 
to as differentiated.
To confirm the phenotypic switch of neuroblastoma 
cells, we analysed the effects of differentiation at a 
molecular level. Immunocytochemical analysis showed 
an increase in the BoNT/C binding substrate GT1b 
following differentiation and the neuronal marker β-III 
tubulin (Figure 2A). The increase in β-III tubulin levels 
was quantified by immunoblotting and was shown to be 
two-fold (Figure 2B, 2C). Immunoblotting also revealed 
a three-fold increase in the level of the neuron-specific 
Tau proteins and a two-fold increase in synaptic vesicle 
glycoprotein 2A (SV2A), a binding target for BoNT type 
Figure 1: Naive human neuroblastoma cells are resistant to botulinum neurotoxin type C-induced cyto-
toxicity. A. Immunoblots showing cleavage of SNAP25 and syntaxin 1 in SiMa and SH-SY5Y neuroblastoma cells following application 
of BoNT/C (100 nM). BoNT/C hydrolyses 8 and 35 amino acids from the C-termini of SNAP25 and syntaxin1, respectively [16]. Alpha-
tubulin was used as a loading control. B. Graph showing undifferentiated neuroblastoma cell counts in the presence of 100 nM BoNT/C 
expressed as a percentage of untreated cells (n=3, mean ± SEM).
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A (Figure 2B, 2C). Taken together, these data confirm 
strong neuronal differentiation of SiMa cells. No 
difference in the BoNT type A and C enzymatic substrate 
- SNAP25 - was observed following differentiation. 
Crucially, differentiation led to a dramatic decrease 
in SNAP23, a ubiquitous homologue of SNAP25, to 
almost undetectable levels (Figure 2B, 2C). SNAP23 
is thought to be essential for cell survival [21] and it 
can substitute SNAP25 in the genetic knockout models 
thereby preventing neuronal death [15]. This indicates 
that the depletion of SNAP25 caused by BoNT/C in 
differentiated neuroblastoma cells may result in cell 
death.
Differentiation increases BoNT/C potency 
and sensitises SiMa cells to BoNT/C-induced 
cytotoxicity
The increased levels of ganglioside Gt1b observed 
after differentiation of SiMa cells suggested an increase in 
the level of BoNT/C binding. To confirm this, a BoNT/C 
Receptor binding domain (Rbd/C, Figure 3A) tagged 
with Cy3 fluorescent marker was generated by a peptide 
stapling technique [22]. Live fluorescence imaging showed 
a marked increase in binding of the Rbd/C-Cy3 following 
differentiation (Figure 3B) with a ten-fold increase in 
SNAP25 and syntaxin cleavage by BoNT/C as observed 
by immunoblotting (Figure 3C, 3D).
We next investigated the effect of BoNT/C SNARE 
cleavage on cell viability. Morphological analysis showed 
that 30 nM of BoNT/C caused a loss of neurites and 
cell rounding in the differentiated cells, whereas the 
undifferentiated cells grew normally (Figure 4A). A large 
drop in cell number was also observed after differentiation, 
with an EC50 of 10 nM (Figure 4B). Hoechst 33342 
nuclear staining revealed that BoNT/C causes nuclear 
condensation in differentiated cells, indicative of 
apoptosis (Figure 4C). This was confirmed by a caspase 
3/7 activation assay which showed a large level of caspase 
activation in differentiated cells after BoNT/C treatment 
(Figure 4D) similar to neuronal apoptosis triggered by 
BoNT/C [14, 15].
Figure 2: Differentiated SiMa cells exhibit enhanced expression of common neuronal markers and a decrease in 
SNAP23 content. A. Immunofluorescent images showing expression of βIII-tubulin, GT1b ganglioside and SNAP25 in SiMa cells 
before and after differentiation. B. Immunoblot showing an increase in expression of neuronal βIII-tubulin, SV2A and tau proteins upon 
differentiation. SNAP25 content remains stable during differentiation whereas SNAP23 content drops significantly. C. Graph showing 
quantification of immunoblotting signals for indicated proteins (n=3, mean± SEM).
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The BoNT/C protease shows higher cytotoxic 
potency than translation-inhibiting enzymes
The observed cytotoxic properties of BoNT/C 
can be utilised in future treatment of neuroblastomas. 
However, in order to be a viable treatment, BoNT/C would 
need to show a high level of potency upon entry into cells. 
A number of translation-inhibiting enzymes including 
saporin, gelonin and diphtheria toxins exhibit very high 
potency, meaning that only a small amount of enzyme 
needs to be introduced into the cell to cause cell death [5]. 
We have recently shown that enzymes can be efficiently 
introduced into cells using the DNA transfection 
reagent lipofectamine 3000 (LF3000) allowing direct 
comparison of enzymatic cytotoxic potential [23]. We 
directly compared the efficacy of the BoNT/C protease 
(i.e. without the Rbd and the translocation domain) 
against saporin, gelonin and the enzymatic domain of the 
diphtheria toxin (Figure 5A). Incubation of differentiated 
SiMa neuroblastoma cells over 72 hours revealed that the 
BoNT/C protease had at least a 10-fold higher potency 
than the other enzymes tested (Figure 5B). This suggests 
that BoNT/C protease is highly toxic upon entry into the 
cell, making it a promising therapeutic payload against 
residual neuroblastoma cells.
Differentiated SH-SY5Y cells also undergo 
BoNT/C protease-induced cytotoxicity
Next we investigated the cytotoxic effects of 
BoNT/C on widely used human SH-SY5Y neuroblastoma 
cells. Differentiation of the SH-SY5Y cell line was carried 
out using the same method as SiMa cells. As with SiMa 
cells, the BoNT/C protease delivered by lipofection 
caused a pronounced neurite loss and cell rounding 
accompanied by a decrease in cell count of differentiated 
Figure 3: Differentiation of SiMa cells results in enhanced botulinum type C binding and SNARE cleavage. A. Schematic 
showing three constituent parts of botulinum neurotoxin. Receptor-binding domain (Rbd, red) can be expressed separately and labelled 
with a fluorescent dye. B. Fluorescent image showing that differentiated SiMa cells exhibit enhanced binding of fluorescent Rbd-Cy3. 
Immunoblot C. and its quantification D. demonstrating ten-fold increase in SNAP25 and syntaxin 1 cleavage induced by BoNT/C upon 
differentiation of SiMa cells (n=3, mean± SEM).
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cells (Figure 6A, 6B). Immunoblotting revealed that 
differentiation of SH-SY5Y cells enhanced SNARE 
cleavage and led to a significant decrease in SNAP23 
content (Figure 6C) confirming that SNARE loss in 
neuroblastoma cells could be responsible for cell death.
DISCUSSION
Treatment of neuroblastomas will benefit from 
introduction of novel agents which can kill required cells 
with highest possible specificity. Here we demonstrated 
that differentiation of neuroblastoma cells sensitises them 
to BoNT/C protease-induced cytotoxicity. Enzymes are 
currently being investigated for the targeted treatment of 
cancer owing to their catalytic properties. Conventional 
enzymes, such as gelonin, saporin and diphtheria toxin 
block protein translation by inactivating either ribosomes 
or elongation factors [24]. However, due to the importance 
of protein synthesis targeted by these enzymes, all cells, 
both healthy and malignant, are potentially vulnerable 
with hepatotoxicity and capillary leak syndrome being 
common [9]. We have shown that the BoNT/C enzyme 
is significantly more potent than saporin and diphtheria 
when delivered into differentiated SiMa cells. Such 
potency makes the BoNT/C protease a possible candidate 
for targeted therapeutic applications especially because 
it only cleaves neuron-specific SNAREs. This makes 
botulinum C protease considerably more specific than 
conventional translation-inhibiting enzymes. Treatment 
of neuroblastomas involves the use of retinoic acid after 
chemotherapy to induce differentiation and stop growth 
of residual cells [25]. Our results suggest that BoNT/C 
protease coupled to neuroblastoma-specific antibodies 
could help to destroy remaining neuroblastoma cells to 
help prevent relapse. It is worth mentioning that whereas 
normally the full BoNT/C neurotoxin binds neurons 
via recognition of complex gangliosides such as GT1b, 
neuroblastomas express simpler gangliosides GD2 and 
GD3 which can be efficiently targeted by antibodies 
[12, 26]. Further work is needed to investigate enzyme 
Figure 4: Differentiated SiMa cells undergo BoNT/C-induced apoptotic death. A. Microscopy images showing dying cells 
only in the case of differentiated neuroblastoma cells in the presence of BoNT/C (30 nM). B. Graph showing dose-dependent cytotoxic 
effect of BoNT/C on SiMa cells, before and after differentiation, normalised to botulinum-untreated controls (EC50=10 nM, n=3, mean± 
SEM). C. Intensive Hoechst nuclear staining demonstrates apoptosis in the case of BoNT/C-treated neuroblastoma cells as confirmed by a 
graph showing caspase 3/7 activation (n=3, mean± SEM) D.
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Figure 5: Botulinum type C protease is cytotoxic following intracellular delivery. A. SDS gel showing botulinum type C protease 
and the indicated translation-inhibiting enzymes. B. Graph showing ten-fold higher vulnerability of differentiated SiMa cells to the botulinum 
protease (EC50=0.5 nM) in comparison to common translation-inhibiting enzymes. All enzymes were delivered into differentiated SiMa cells 
using LF3000 lipofection reagent (n=3, mean± SEM). Cell counts were normalised to botulinum-untreated controls (LF3000 alone).
Figure 6: Differentiated SH-SY5Y neuroblastoma cells exhibit sensitivity to botulinum type C protease. A. The botulinum 
protease, introduced into cells by lipofection, causes cell death only in retinoic acid-differentiated cells. B. Graph showing dose-dependent cytotoxic 
effect of BoNT/C, before and after differentiation, normalised to botulinum-untreated controls (EC50=1 nM, n=3, mean± SEM). C. Immunoblots 
showing botulinum protease-induced SNARE cleavage and drop in SNAP23 content upon neuronal differentiation of SH-SY5Y cells.
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coupling and delivery strategies to achieve novel 
therapeutics for neuroblastomas and this may involve re-
engineering of both the C protease and its translocation 
domain. Recently, an engineered version of botulinum 
neurotoxin type D was shown to be therapeutically 
relevant in the treatment of acromegaly opening new 
avenues for the use of engineered botulinum constructs in 
medicine [27].
The mechanism by which differentiation sensitises 
neuroblastomas to BoNT/C protease most likely involves 
the double loss of ubiquitous SNAP23 and neuron-specific 
SNAP25 activity. These two SNAREs are known to be 
necessary for important plasma membrane functions such 
as exocytosis and membrane recycling [28]. A recent study 
has shown that knockdown of ubiquitous SNAP23 leads 
to cell death in a number of cell models, suggesting a vital 
role for this SNARE in maintaining cell viability [21]. 
Crucially, exogenous expression of SNAP23 can rescue 
hippocampal neurons from BoNT/C-induced cytotoxicity 
[15] demonstrating that SNAP25 and SNAP23 are 
functionally redundant and only in the case of their 
simultaneous inactivation apoptosis ensues. The observed 
cleavage and loss of syntaxin1, and related plasma 
membrane isoforms [16], likely compound deficiencies 
in membrane trafficking leading to exquisite sensitivity 
of neuroblastoma cells to BoNT/C action. The extent of 
SNAP23 downregulation in neuroblasts following retinoic 
acid treatment in vivo is currently unknown and will be 
an important future consideration for botulinum-based 
therapies.
In this study we also demonstrated that under 
defined conditions SiMa cells can express mature 
neuronal markers such as Tau and β-III tubulin making 
this neuroblastoma cell line a useful replacement model 
for neurobiological studies relying on animal-derived 
primary cultures. The simple BoNT/C cell death assay 
using standardised cell cultures can be utilised in detection 
of this dangerous neurotoxin affecting cattle and poultry, 
thereby eliminating the current requirement for live rodent 
bioassays. Future enhancement of sensitivity may involve 
the addition of GT1b ganglioside for assaying the full 
neurotoxin as was recently shown for therapeutic BoNT/A 
preparations [18].
In summary, our study highlights the potential 
utility of botulinum type C protease in the treatment of 
neuroblastomas and also sheds light on SNARE function 
in cell survival which can be exploited in future research 
and drug development.
MATERIALS AND METHODS
Toxins and recombinant proteins
The enzymatic domain of the diphtheria toxin, the 
BoNT/C protease and the full BoNT/C neurotoxin were 
described previously [17, 23, 29]. Saporin from Saponaria 
officinalis seeds was purchased from Sigma and gelonin 
isolated from Gelonium multiform was purchased from 
Enzo Life Sciences. Cy3-Rbd/C was formed in a stapling 
reaction [20] by mixing SNAP25-Cy3, synaptobrevin-
Rbd/C and a syntaxin SNARE helix peptide at equimolar 
ratios in Buffer A (100 mM NaCl, 20 mM HEPES, 0.4% 
n-octylglucoside, pH 7.4). SNAP25-Cy3 was prepared 
by conjugating Cy3-NHS ester to the free cysteine of 
SNAP25 W105A.
Cell culture
SiMa cells (DSMZ) were grown in RPMI media 
(Life Technologies) supplemented with 10% Fetal Bovine 
Serum (FBS) (Life Technologies). SH-SY5Y cells (Sigma) 
were grown in a 1:1 mix of MEM (Life Technologies) and 
F12 nutrient mix (Life Technologies) supplemented with 
15% FBS and 1% non-essential amino acids (NEAA) 
(Life Technologies). Cells were maintained at 37°C, 5% 
CO2. Cell lines were frozen after receiving from supplier 
and were not used for more than 20 passages (10 weeks).
For differentiation, plates were pre-coated with 10 
µg/ml laminin (Sigma) and left at 37°C for at least one 
hour before washing twice with PBS. SiMa cells were 
seeded at a density of 1 x104 cells per well in 96-well plates 
or 2 x104 cells per well in 48-well plates and incubated for 
72 hours in differentiation medium (RPMI, 1x B27 (Life 
Technologies), 1 mM HEPES (Fisher) and 1% NEAA) 
with or without 10 µM AT-RA (Sigma). SH-SY5Y cells 
were seeded at 5 x103 cells for 96-well plates and 2 x104 
cells for 48-well plates. They were differentiated for 
144 hours, using the same differentiation media as SiMa 
cells, before treatment. 96-well plates with a µClear base 
(Greiner Bio-one) were used for microscopy.
Protein transduction
Delivery of the C protease, saporin, gelonin and 
the diphtheria enzyme into cells using the lipofectamine 
3000 (LF3000) reagent (Life Technologies) was carried 
out as described previously [23]. Protein solutions were 
prepared in Optimem (Life Technologies) at 10x required 
concentration with LF3000 (1-2 µl in 100 µl) and then 
incubated at 20˚C for 20 minutes before application to 
cells (10 µl of protein solution to 90 µl of culture medium).
Cell count and viability assays
Cells were washed with PBS and then trypsinised. 
After detachment cells were diluted to 100 μl in media 
before counting using an automated cell counter (Biorad). 
The effect of BoNT/C and other enzymes on cell numbers 
was measured using cell-counting kit 8 (CCK8) assay 
(Sigma) according to manufacturer’s instructions. After 
treatments, the CCK8 reagent was added to cells in a 1:10 
dilution and incubated for 90 minutes at 37°C, before 
absorbance was read on a plate reader (Biorad) at 450nm. 
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Cell numbers are shown as a percentage of the untreated 
control after subtraction of the background (media plus 
CCK8 without cells).
Microscopy assays
For imaging of BoNT/C Rbd binding, cells were 
seeded in 96-well µClear plates. Cy3-labelled BoNT/C 
Rbd (60 ng/ml) was incubated with the cells for 45 
minutes at 37°C. 1 µg/ml Hoechst 33342 stain (Life 
Technologies) was added for nuclear staining. Cells were 
washed 5 times with PBS before imaging using a digital 
fluorescence microscope (DMIRB, Leica Microsystems) 
and a 40x objective. Nuclear morphology was assessed by 
incubating cells with 1 μg/ml Hoechst 33342 at 37°C for 
15 minutes before imaging with a 40x objective. Caspase 
3/7 activity was measured using the CellEvent Caspase 
3/7 Green detection kit (Life Technologies) according to 
manufacturer’s instructions. CellEvent reagent was added 
to cells at a final concentration of 5 µM and cells were 
incubated for 15 minutes at 37°C. Then, 1 μg/ml Hoechst 
33342 was added and cells were incubated for a further 
15 minutes at 37°C before imaging under a fluorescence 
microscope at 40x objective. Experiments were performed 
in duplicate, and at least 4 images were taken per well. 
Fluorescent cells were counted using ImageJ and 
apoptosis was calculated as a percentage of total cells. 
Immunocytochemistry was performed on cells grown in 
96-well μClear plates. Cells were washed with PBS, fixed 
in 4% paraformaldehyde and then permeabilised using 
PBS-0.1% triton. Cells were then saturated in a blocking 
solution for one hour before incubation with primary 
antibodies for 2 hours at 20˚C. Primary antibodies were 
used at the following concentrations: β-III tubulin (R&D 
Systems, 1:2000), SNAP25 (In-house, 1:500 [30]) and 
GT1b (1:500). Following washing in PBS, cells were 
incubated with DAPI stain (Sigma) and the Alexa Fluor 
488 conjugated goat anti-mouse or anti-rabbit secondary 
antibodies (Life Technologies) for 45 minutes. Cells 
were washed 3 times in PBS before imaging with a 40x 
objective.
Immunoblotting
Immunoblotting was performed as described 
previously [17]. Briefly, cells were lysed in sample buffer 
(56 mM sodium dodecyl sulfate, 62.5 mM Tris-HCl pH 
6.8, 1.6 mM EDTA, 6.24% glycerol, trace bromophenol 
blue, 1 mM MgCl2 and 0.1% benzonase). Protein 
concentration was measured using the DC assay (Biorad) 
according to manufacturer’s instructions. Lysates were run 
on 12% Bis-Tris sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) gels (Invitrogen) and 
protein was transferred to a polyvinylidene difluoride 
membrane (Biorad) before probing with antibodies. 
Primary antibodies used include SNAP25 (In-house, 
1:4000), SNAP23 (Synaptic Systems, 1:4000), Syntaxin 
1 (In-house, 1:1000 [30]), SV2A (Synaptic Systems, 
1:2000), Tau (1:1000), α-tubulin (1:10 000, Sigma) 
and β-III tubulin (R&D Systems, 1:1000). Following 
incubation with peroxidase conjugated sheep anti-
mouse or donkey anti-rabbit secondary antibodies (1:24 
000, GE Healthcare), proteins were visualised using the 
SuperSignal West Dura ECL reagent (Thermo Scientific) 
by X-ray film exposure with signals quantified using 
ImageJ after film scanning.
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